AU2019287623B2 - General amyloid interaction motif (GAIM) - Google Patents

General amyloid interaction motif (GAIM) Download PDF

Info

Publication number
AU2019287623B2
AU2019287623B2 AU2019287623A AU2019287623A AU2019287623B2 AU 2019287623 B2 AU2019287623 B2 AU 2019287623B2 AU 2019287623 A AU2019287623 A AU 2019287623A AU 2019287623 A AU2019287623 A AU 2019287623A AU 2019287623 B2 AU2019287623 B2 AU 2019287623B2
Authority
AU
Australia
Prior art keywords
gly gly
amyloidosis
gaim
glu
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019287623A
Other languages
English (en)
Other versions
AU2019287623A1 (en
Inventor
Eva ASP
Richard Fisher
Rajaraman Krishnan
Ming PROSCHITSKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amyl Therapeutics Srl
Original Assignee
Amyl Therapeutics Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amyl Therapeutics Srl filed Critical Amyl Therapeutics Srl
Publication of AU2019287623A1 publication Critical patent/AU2019287623A1/en
Assigned to AMYL THERAPEUTICS SRL reassignment AMYL THERAPEUTICS SRL Request for Assignment Assignors: PROCLARA BIOSCIENCES, INC.
Application granted granted Critical
Publication of AU2019287623B2 publication Critical patent/AU2019287623B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2019287623A 2018-06-15 2019-06-14 General amyloid interaction motif (GAIM) Active AU2019287623B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862685757P 2018-06-15 2018-06-15
US62/685,757 2018-06-15
US201862749499P 2018-10-23 2018-10-23
US62/749,499 2018-10-23
PCT/US2019/037179 WO2019241628A1 (en) 2018-06-15 2019-06-14 General amyloid interaction motif (gaim)

Publications (2)

Publication Number Publication Date
AU2019287623A1 AU2019287623A1 (en) 2021-01-07
AU2019287623B2 true AU2019287623B2 (en) 2024-11-07

Family

ID=67263052

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019287623A Active AU2019287623B2 (en) 2018-06-15 2019-06-14 General amyloid interaction motif (GAIM)

Country Status (13)

Country Link
US (2) US11692017B2 (enExample)
EP (2) EP3806884B1 (enExample)
JP (1) JP7549536B2 (enExample)
CN (1) CN112672755A (enExample)
AU (1) AU2019287623B2 (enExample)
BR (1) BR112020025111A2 (enExample)
ES (1) ES2960493T3 (enExample)
IL (1) IL279333B2 (enExample)
MX (1) MX2020013525A (enExample)
PL (1) PL3806884T3 (enExample)
SG (1) SG11202012091WA (enExample)
WO (1) WO2019241628A1 (enExample)
ZA (1) ZA202100071B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法
CN117343200B (zh) * 2023-12-04 2024-01-30 北京质肽生物医药科技有限公司 一种包含淀粉样核心多肽的融合蛋白、制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1673395A1 (en) 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US9493515B2 (en) * 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) * 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) * 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ， インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 ｇ3ｐ 아미노산 서열을 포함하는 폴리펩티드
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAJARAMAN KRISHNAN ET AL: "A Bacteriophage Capsid Protein Provides a General Amyloid Interaction Motif (GAIM) That Binds and Remodels Misfolded Protein Assemblies", J. Mol. Biol., vol. 426, no. 13, 2014, pages 2500 - 2519 *

Also Published As

Publication number Publication date
US12247055B2 (en) 2025-03-11
EP4389154A2 (en) 2024-06-26
SG11202012091WA (en) 2021-01-28
IL279333B2 (en) 2023-06-01
IL279333A (en) 2021-01-31
US11692017B2 (en) 2023-07-04
CA3102841A1 (en) 2019-12-19
US20210246179A1 (en) 2021-08-12
EP3806884C0 (en) 2023-08-02
WO2019241628A1 (en) 2019-12-19
ES2960493T3 (es) 2024-03-05
JP2021527407A (ja) 2021-10-14
BR112020025111A2 (pt) 2021-04-06
ZA202100071B (en) 2023-04-26
EP3806884B1 (en) 2023-08-02
JP7549536B2 (ja) 2024-09-11
EP3806884A1 (en) 2021-04-21
MX2020013525A (es) 2021-02-26
EP4389154A3 (en) 2024-11-13
AU2019287623A1 (en) 2021-01-07
US20230279064A1 (en) 2023-09-07
CN112672755A (zh) 2021-04-16
PL3806884T3 (pl) 2023-11-20

Similar Documents

Publication Publication Date Title
US12247055B2 (en) General amyloid interaction motif (GAIM)
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
JP6440765B2 (ja) アミロイド結合剤としてのバクテリオファージのｐ３の使用
EP3003349A1 (en) Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
JP2017538407A (ja) グリコシル化シグナルを欠く改変バクテリオファージｇ３ｐアミノ酸配列を含むポリペプチド
CA3102841C (en) General amyloid interaction motif (gaim)
HK40110180A (en) General amyloid interaction motif (gaim)
HK40049127B (en) General amyloid interaction motif (gaim)
HK40049127A (en) General amyloid interaction motif (gaim)
EA046070B1 (ru) Общий амилоид-взаимодействующий мотив (gaim)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AMYL THERAPEUTICS SRL

Free format text: FORMER APPLICANT(S): PROCLARA BIOSCIENCES, INC.

FGA Letters patent sealed or granted (standard patent)